ReviewInternational journal of nanomedicine2025
Recent Progress in Nano-TCM Active Ingredient Co-Delivery Systems for Inflammation-Mediated Diseases.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Mechanistic and Clinical Perspectives on Traditional Chinese Medicine in Thyroid Cancer Management.Biomolecules & therapeutics · 2026Review
- Chinese Medicine Reduces Treatment Failure in Elderly Patients with Severe Community-Acquired Pneumonia: A Post-Hoc Analysis of a Randomized Controlled Trial.Chinese journal of integrative medicine · 2026Article
- Mechanisms of resveratrol in cartilage injury repair and protection: A review.The Journal of international medical research · 2026Review
- Artificial intelligence-enabled cross-scale integration of traditional Chinese medicine and biomedicine for sepsis: from mechanisms to delivery.Frontiers in pharmacology · 2026Review
- Formulation Progress, Challenges, and Perspectives of Anti-Inflammatory Natural Products.Drug design, development and therapy · 2026Review
- Nanotechnology-driven synergy in cardio-oncology: enhancing tumor suppression and reducing cardiotoxicity.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is a pivotal pathogenic factor in numerous diseases. Traditional Chinese medicine (TCM) has garnered significant attention due to its rich bioactive compounds with demonstrated anti-inflammatory and antioxidant activities. Nevertheless, clinical translation of TCM is often limited by poor pharmacokinetic properties, including low solubility, rapid clearance, and inadequate biomembrane permeability. Nanocarrier-based delivery systems have emerged as a promising strategy to overcome these limitations and enhance therapeutic outcomes. This review systematically summarizes: (1) the anti-inflammatory mechanisms of key TCM-derived compounds (resveratrol, quercetin, curcumin, honokiol, bergenin, ginsenosides, and berberine); (2) the classification and functional advantages of contemporary nanocarriers; and (3) recent advances in nanoengineered co-delivery systems for TCM active ingredients against inflammation-associated pathologies. Furthermore, we critically analyze persisting challenges and propose future directions to optimize nano-TCM platforms, offering new perspectives for targeted therapy of inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.